Bromfenac(0.0032-3.16%;100or200μL;rubbedontothebacks)producessignificantanti-inflammatoryactivityatconcentrationsaslowas0.1%(4hpretreatmenttime)or0.32%(18hpretreatmenttime)inrats.Bromfenac(0.032-3.16%;100μL;rubbedontothepaws)producesdose-relatedanti-inflammatoryactivityinrats.Bromfenac(0.032-1.0%;50μL)is26timesmorepotentthanindomethacininblockingtheerythemawhenapplieddirectlyontotheskinareaexposedtoUVlightinguineapigs.Bromfenac(0.0032-0.1%;50μL;rubbedontotheuninjectedpawfor4hperdayand5daysperweek)producesadoseandtimedependentreductioninthepawvolumeofbothhindlimbsinrats.Bromfenac(0.32%;50μL;rubbedontotheabdomen)producessignificantblockadeofabdominalconstrictiontoAChchallengeinmice.AnimalModel:MaleSprague-Dawleyrats(150-250g)areinjectedcarrageenanDosage:0.0032,0.01,0.032,0.1,0.32,1.0,3.16%(100or200μL)Administration:Rubbedontothebacksbefore1-72hofinjectedcarrageenanResult:Producedsignificantanti-inflammatoryactivitywhenapplied1,2,and4hpriortocarrageenanchallengeat0.32%.Applied1or4hpriortocarrageenanchallengewasactive,butnotwhenapplied24h(orlonger)priortochallengeat0.2%.